A Clinical Randomized Controlled Trial of the New Method of Selective Coronary Vein Bypass Graft (SCVBG)
|ClinicalTrials.gov Identifier: NCT03334110|
Recruitment Status : Unknown
Verified November 2017 by Yang Yu, Beijing Anzhen Hospital.
Recruitment status was: Recruiting
First Posted : November 7, 2017
Last Update Posted : November 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Coronary Atherosclerotic Heart Disease||Procedure: A method of operation: LIMA-GSV-SCVBG Procedure: BIMA-SCVBG||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||320 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Clinical Randomized Controlled Trial of the New Method of Selective Coronary Venous Bypass Graft on Improving Curative Effects in Patients With Diffuse Coronary Artery Disease|
|Estimated Study Start Date :||November 30, 2017|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||September 2018|
Experimental: LIMA-GSV-SCVBG Group
Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.
Procedure: A method of operation: LIMA-GSV-SCVBG
On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.
On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
- The patency rate of bridge vessels and selective coronary vein [ Time Frame: 1-3 years ]We will assess the patency rate during a follow-up of 1 year, and continue to follow up to 3 years after the end of the project
- Main adverse cardiovascular and cerebrovascular events [ Time Frame: 1-3 years ]We will follow up the main adverse cardiovascular and cerebrovascular events ( death, myocardial infarction, stroke and repeated revascularization) 7 days, 1 month, 3 months, 6 months and 1 year after the operation and continue to 3 years.
- Wound complications [ Time Frame: 1-3 years ]We will follow up the wound complications (sternum and mediastinal infection, incision infection, fat liquefaction) 7 days, 1 month, 3 months, 6 months and 1 year after the operation and continue to 3 years.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03334110
|Beijing An Zhen Hospital , Capital Medical University||Recruiting|
|Beijing, Beijing, China|
|Contact: yang yu, doctor 13911534101 firstname.lastname@example.org|